Glucagon (19 – 29), bovine, human, porcine CAS NO.64790-15-4

Glucagon (19 – 29), bovine, human, porcine CAS NO.64790-15-4

Glucagon (19 – 29), bovine, human, porcine CAS NO.64790-15-4

Glucagon (19 – 29), bovine, human, porcine CAS NO.64790-15-4

Glucagon (19 – 29), bovine, human, porcine CAS NO.64790-15-4

Glucagon (19-29) is a conserved 11-amino acid fragment (sequence: Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val) derived from the C-terminal region of the full-length glucagon hormone. This peptide represents residues 19-29 of the glucagon sequence, which is identical across bovine, human, and porcine species, highlighting its evolutionary importance. While it lacks the full hyperglycemic activity of intact glucagon, this fragment possesses distinct biological properties and serves as a crucial tool for studying glucagon receptor interaction domains, structure-activity relationships, and potential alternative signaling functions. It is supplied as a high-purity synthetic lyophilized powder for specialized research applications.



TECHNICAL SPECIFICATIONS


Item
Specification
Product Name
Glucagon (19-29), bovine, human, porcine
CAS NO.
64790-15-4
Appearance
White lyophilized powder
Molecular Formula
C61H89N15O18S
Molecular Weight
1352.54g/mol 
Purity (RP-HPLC)
≥98%
Solubility

Soluble in water and aqueous buffers; partial solubility in polar organic solvents.

Endotoxin≤50 EU/mg
Biological Activity
 Active fragment of glucagon with receptor-binding activity.
Storage Conditions
Store desiccated at ≤-20°C in dark condition, sealed to avoid moisture.
Stock Location
Stock in USA
MOQ
1g


1.MECHANISM OF ACTION

  • Receptor Interaction Domain: This region is part of the glucagon molecule's receptor binding domain. The fragment itself may act as a partial agonist or weak antagonist, potentially competing with full-length glucagon for receptor binding without eliciting full Gs-protein mediated cAMP signaling.

  • Modulation of Signaling: It may bind to the GCGR and induce biased signaling, activating pathways different from those triggered by the full hormone (e.g., β-arrestin recruitment instead of strong cAMP production).

  • Novel Receptor Target: There is evidence suggesting it may interact with other, yet uncharacterized, receptors to mediate specific physiological effects separate from the classic glucagon action.

  • Functional Role: Studies indicate it may influence cell proliferation, have neuroactive properties, or modulate the activity of other regulatory peptides.


    • 2.PRODUCT INDICATIONS

    • Structure-Activity Relationship (SAR) Studies: Mapping the critical regions of glucagon required for receptor binding and activation by comparing the properties of this fragment with the full-length hormone and other analogs.

    • Glucagon Receptor (GCGR) Pharmacology: Serving as a tool peptide in competitive binding assays to study the receptor's interaction site and to probe for allosteric modulatory effects.

    • Biased Agonism Research: Investigating whether this fragment can induce selective signaling pathways (e.g., β-arrestin) at the GCGR, a key concept in modern drug discovery for metabolic diseases.

    • Antagonist/Inhibitor Development: Used as a starting point or reference for designing novel glucagon receptor antagonists or modulators for conditions like hyperglycemia.

    • Neuroscience Research: Exploring potential neurotrophic or neuromodulatory effects of glucagon-derived peptides in the central nervous system.

    • Comparative Biology Studies: Utilizing its conserved sequence to investigate fundamental peptide-receptor interactions across species.


      3.CLINICAL EFFICACY OF PRODUCT

    • Research Significance: Its "efficacy" is defined in a research context by its ability to provide insights into glucagon biology. It has been instrumental in identifying the core receptor-binding region of glucagon and understanding how different parts of the hormone contribute to its overall function.

    • Drug Discovery Tool: Research on this and similar fragments is critical for the rational design of novel glucagon receptor modulators. For example, understanding the receptor interaction site helps in developing antagonists for diabetes or biased agonists that may separate beneficial metabolic effects from hyperglycemia.

    • Therapeutic Concepts: While the fragment itself is not a drug candidate, the knowledge gained from studying it contributes to the development of:
      • Glucagon receptor antagonists for type 2 diabetes (to reduce hepatic glucose output).

      • Dual or triple agonists (e.g., GLP-1/glucagon co-agonists) for obesity and NASH, where modulating glucagon signaling is a key component.

    • Clinical Status: No clinical trials have been conducted with Glucagon (19-29). Its value is entirely preclinical, providing the foundational science for future drug development targeting the glucagon pathway.


    • 4.DELIVERY & SHIPPING

      We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
      Professional and Secure Packaging
      Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
      We can also customize packaging according to customer needs.
      Shipping Methods 
      Main Method: International Air Freight

      We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.

Premium API Oxandrolone Ucinky Manufacturing
May 25, 26
Premium API Oxandrolone Ucinky Manufacturing
Premium API Oxandrolone Ucinky Manufacturing Leading global supplier of high-purity chemical raw materials for pharmaceutical grade Oxandrolone Ucinky, combining precision engineering with industrial scale. 5000 kg Annual Output 120 Countries Served 5 Days Sample Lead Time 99.7 On-Time Delivery Industrial Precision Pure Chemical Synthesis Engineering the future of pharmaceutical intermediates with unmatched stability. Our facility stands as a global leader in the oxandrolone ucinky sector, utilizing CRYOGENIC CRYSTALLIZATION and advanced chromatography to ensure an assay purity exceeding 99.8. We integrate a fully automated closed-loop system that eliminates human error and contamination.
Clinical Benefits and Applications of Oxandrolone Therapy
May 22, 26
Clinical Benefits and Applications of Oxandrolone Therapy
Oxandrolone therapy represents a sophisticated intersection of endocrine science and regenerative medicine, primarily utilized to address muscle wasting and metabolic dysfunction. In the global pharmaceutical landscape, this specific approach to androgen therapy is valued for its unique ability to promote protein synthesis while exhibiting a lower androgenic profile compared to traditional steroids, making it a critical tool for patients recovering from severe trauma or chronic illness. From a clinical perspective, understanding the nuances of oxandrolone therapy is essential for optimizing patient outcomes in weight gain and tissue repair.
Clinical Benefits and Production of Oxandrolone Steroid
May 20, 26
Clinical Benefits and Production of Oxandrolone Steroid
The global pharmaceutical landscape has seen a significant rise in the demand for highly specialized anabolic agents, among which the oxandrolone steroid stands out due to its unique chemical profile and therapeutic versatility. As a modified version of dihydrotestosterone, this compound provides a potent means of addressing muscle wasting and metabolic deficits, making it a critical asset in both clinical rehabilitation and advanced physiological research. Understanding the nuances of this synthetic compound is essential for healthcare providers and researchers alike, as it balances efficacy with a relatively lower androgenic profile compared to other steroids.

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.